Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-75,page-paged-75,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • CENTOGENE Accelerates Rare Disease Diagnosis with new Artificial Intelligence Solution
    www.centogene.com
  • Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology
    www.vivoryon.com
  • Medigene AG: Interim analysis from ongoing Phase I/II clinical trial with DC vaccines in AML patients presented at EHA
    www.medigene.com
  • InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum
    www.inflarx.com
  • CENTOGENE Launches Research Study to Unravel the Genetics of Hypophosphatasia
    www.centogene.com
  • Probiodrug AG becomes Vivoryon Therapeutics AG
    www.vivoryon.com
  • Expedeon AG mandates ODDO SEYDLER BANK AG as Designated Sponsor
    www.expedeon.com
  • Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD
    www.xenikos.com
  • Heidelberg Pharma Presents Proprietary ATAC Technology Platform at Two Scientific Conferences
    www.heidelberg-pharma.com
  • Motif Bio plc: Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes
    www.motifbio.com